| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8652830 | The Annals of Thoracic Surgery | 2018 | 7 Pages |
Abstract
Induction cisplatin and docetaxel was well tolerated. Adjuvant erlotinib did not improve outcomes compared with historical controls. Major pathologic response predicted for improved long-term survival and is a suitable intermediary endpoint for future phase 2Â studies.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Tina MD, PhD, Kathryn A. MD, Stephen G. MD, Diane D. MS, Frank V. MD, Boris MD, Apar MD, Annikka MD, Neda MD, Ara A. MD, Wayne L. MD, Ignacio I. MD, John V. MD, PhD, Edward S. MD, William N. MD,